Novartis' iron drug Exjade will carry black-box warning

02/18/2010 | Reuters

The FDA announced that Novartis' iron treatment Exjade will come with a black-box warning stating the risk of potentially fatal renal impairment. The drug is approved to level the amount of excess iron caused by blood transfusion.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Teaching Associate (Hospitality Management)
University of Illinois at Urbana-Champaign
Urbana, IL
Director, Global Regulatory Affairs
Rodan and Fields, LLC
San Francisco, CA